Lilly Buys Merida Biosciences for Up to $2.875B to Target Autoantibody-Driven Disease

Eli Lilly said Monday it will acquire Merida Biosciences, a privately held Cambridge, Massachusetts biotech, for up to $2.875 billion in cash to gain a precision platform that selectively degrades the pathogenic autoantibodies behind a range of immune-mediated diseases. The deal includes an upfront payment plus contingent milestone payments and is expected to close in the fourth quarter of 2026, subject to regulatory approvals and customary closing conditions.

Merida’s lead program, MER511, is in Phase 1 development for Graves’ disease and thyroid eye disease (TED), conditions driven by thyroid-stimulating immunoglobulins that activate the thyroid-stimulating hormone receptor. Graves’ disease affects roughly 3 million people in the U.S., and an estimated 25 to 40 percent of patients go on to develop TED, which can cause pain, disfigurement, and, in severe cases, vision loss. While treatments exist for both conditions, none directly targets the autoantibodies that cause them.

Early Phase 1 data showed MER511 produced deep reductions in those disease-causing antibodies with a favorable initial safety profile. The mechanism differs from Amgen’s Tepezza (teprotumumab), the approved TED therapy that blocks the IGF-1 receptor. MER511 is designed to eliminate the autoantibodies themselves while preserving normal immune function, an approach Lilly says could change the course of disease rather than only treating its downstream effects.

The platform reaches beyond the lead program. Merida’s pipeline also includes MER769, a preclinical candidate aimed at food allergy, asthma, and chronic spontaneous urticaria, plus earlier-stage programs in kidney diseases such as membranous nephropathy.

Lilly shares traded near $1,159 midday Monday, down about 1 percent from Friday’s close of $1,174.61. For a company of Lilly’s size, a sub-$3 billion bolt-on barely registers, but the deal extends a heavy year of dealmaking: it follows Lilly’s $2.8 billion buyout of AtaiBeckley in July and is one of more than a dozen acquisitions the drugmaker has struck in 2026.

The move gives Lilly a direct challenger to Amgen in thyroid eye disease and deepens an immunology franchise built around inflammatory and autoimmune disease. Watch for additional Phase 1 data from MER511 and whether Lilly advances the asset toward registrational trials in Graves’ disease.

The full press release is available from Lilly. For context on Lilly’s earlier M&A push, see our coverage of the AtaiBeckley acquisition.

What It Means for the Trade

Size the move correctly: for Lilly, this is a sub-$3 billion bolt-on against a company with the largest market cap in pharma — the stock’s 1% dip on announcement day is noise, not signal. What matters is the strategic pattern. Lilly spent 2026 running one of the most aggressive bolt-on programs in the industry (more than a dozen deals, including the $2.8 billion AtaiBeckley psychedelic-adjacent buyout in July), and the common thread is mechanism-platform acquisition: pay early, before registrational data reprices the asset. Merida at Phase 1 for up to $2.875 billion is expensive on conventional biotech math, but if the autoantibody-degradation platform works, it’s cheap against the peak-sales curve of a Graves’/TED franchise plus follow-on allergy and nephrology indications.

The Amgen-competition angle is the part the market will eventually price. Tepezza (teprotumumab) is one of Amgen’s highest-growth orphan assets post-Horizon acquisition, doing roughly $2 billion a year, and its mechanism — IGF-1 receptor blockade — is downstream: it interrupts the fibroblast activation that autoantibodies trigger, without touching the antibodies themselves. Merida’s MER511 aims upstream: eliminate the thyroid-stimulating immunoglobulins and the disease process starves. If that translates into a disease-modifying profile versus Tepezza’s disease-suppressing one, Lilly isn’t buying a competitor, it’s buying the next generation of the category — and Graves’ itself (3 million U.S. patients, mostly treated with decades-old antithyroid drugs, radioiodine, or surgery) is a far larger market than TED alone.

Also note the optionality stack: MER769 in food allergy, asthma, and chronic spontaneous urticaria points at IgE and allergy-adjacent territory where Lilly has been underweight relative to its immunology ambitions, and the membranous nephrology programs give the platform renal credibility. This is a platform bet with a lead-asset catalyst, not a single-molecule bet.

Mechanism Context: Why Autoantibody Degradation Is the Frontier

The immunology investment landscape has spent five years converging on the same insight: the highest-value targets in autoimmune disease are the pathogenic antibodies themselves, not the cells that make them. Three complementary technologies are racing: FcRn blockade (argenx’s Vyvgart, J&J’s IMAAVY — lowers IgG broadly, proven across indications but not antigen-specific), plasma-cell targeting (BCMA/CD38-directed cell therapies and T-cell engagers in autoimmune — deep depletion, heavy safety machinery), and selective autoantibody degradation — Merida’s lane. The pitch for the third: knock down only the disease-causing antibody clone while leaving protective immunity intact, avoiding both FcRn’s broad-IgG blunting and cell-therapy’s complexity.

TED is the proof-ground for a reason: thyroid-stimulating immunoglobulins are a well-characterized, measurable, pathogenic biomarker — the kind of clean antigen-antibody relationship that makes a degradation approach testable. Early Phase 1 showing “deep reductions” in those antibodies with favorable safety is the right signal in the right biomarker. The open question, which only later trials answer, is whether antibody clearance in established disease reverses fibroblast-driven orbital pathology or merely halts progression — Tepezza’s clinical bar in active TED was set by proving proptosis reversal, and matching it mechanistically upstream is the hard part.

Risks and What Could Go Wrong

The standard early-stage-acquisition risks apply with force: MER511 is Phase 1, so the majority of the deal’s contingent value rests on data that doesn’t exist yet, and Lilly has effectively pre-paid a milestone-rich price for biology that could still fail on specificity (degrading the wrong antibody populations), duration (autoantibody-producing plasma cells replenish the pool — the rebound question that defines this whole class), or delivery. If the platform’s degradation math only works for a subset of autoantibody formats, the pipeline breadth (allergy IgE, nephritis IgG4) narrows accordingly.

Strategically, the risks are smaller but real: Amgen won’t cede TED quietly — Tepezza’s commercial infrastructure, its own next-gen TED pipeline, and Horizon’s orphan-disease machine make it a tenacious incumbent; and Lilly’s M&A tempo across 2026 raises integration and focus questions (a dozen-plus acquisitions means a dozen-plus sets of legacy pipelines to triage). Pay close attention to what Lilly says at the next earnings call about MER511’s Phase 2 design and timeline — a 2027 start would be normal pacing; silence or delay would be the first sign the Phase 1 data looked better in the press release than in the clinic.

For LLY holders, the honest takeaway: this deal is a rounding error that adds platform optionality in immunology while the core story — retatrutide’s BLA, orforglipron’s readouts, the obesity+diabetes+oncology triad — does all the earnings work. For anyone building exposure to the autoantibody-degradation theme specifically, this is now a Lilly-subordinate way to own it, which caps the upside but funds it properly.